# Meclizine for Hepatocellular Carcinoma

> **NCT03253289** · PHASE1 · COMPLETED · sponsor: **Tannaz Armaghnay** · enrollment: 13 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Meclizine Oral Tablet

## Key facts

- **NCT ID:** NCT03253289
- **Lead sponsor:** Tannaz Armaghnay
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-13
- **Primary completion:** 2023-03-28
- **Final completion:** 2023-03-28
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03253289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03253289, "Meclizine for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03253289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*